Implementation of soluble CD38 in blood crossmatching for patients on anti‐ CD38 therapy: A single‐center experience
Transfusion · 2026-11 · 66 (11) · 2097-2100
DOI: 10.1111/trf.70389 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transfusion, online erschienen am 11.09.2026. Verfasst von Ayda Javanbakht und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Texas Southwestern, Dallas, Texas, USA. Hauptthemen laut MEDLINE: ADP-ribosyl Cyclase 1, Blood Grouping and Crossmatching, Antibodies, Monoclonal, Membrane Glycoproteins. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Human monoclonal (MoAb) anti‐CD38 antibodies, such as daratumumab, are used to treat diseases such as multiple myeloma. Because red blood cells (RBCs) express CD38, these MoAbs interfere with antibody screening and crossmatching in blood banks. The dithiothreitol (DTT) treatment of reagent cells to destroy CD38, combined with phenotyping/genotyping, has been used to address this interference. Due to anti‐CD38 activity in the patient's plasma, RBC units will be crossmatch incompatible and labeled crossmatch‐incompatible, necessitating communication with the ordering team regarding the safety of blood transfusion. The recombinant soluble CD38 (sCD38) antigen neutralizes the MoAb in a patient's plasma and can be used to perform crossmatches. Here, we describe our experience with sCD38 in RBC crossmatching. Study Design and Method We began using sCD38 (Grifols) for RBC crossmatching in January 2026 (using 6 μL of sCD38 per crossmatch) following completion of a validation study. Because of the known interference of sCD38 with the Duffy blood group system (by denaturation), its use was limited to RBC crossmatching. We use the DTT method for antibody screening tests.
Results
A total of 128 RBC crossmatches were performed for 49 patients on daratumumab. The sCD38 neutralized daratumumab in all crossmatching samples. Thus, all units were labeled crossmatch‐compatible, eliminating the need for provider communication. At the last follow‐up, with type and screen for these patients, no new alloantibody was detected.
Conclusion
Soluble CD38 neutralized the anti‐CD38 MoAb, enabling crossmatch‐compatible RBC units to be issued and obviating the need to notify the provider of apparent incompatibility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, University of Texas Southwestern, Dallas, Texas, USA.
- Transfusion Services, University of Texas Southwestern, Dallas, Texas, USA.
- Department of Internal Medicine, University of Texas Southwestern, Dallas, Texas, USA.
ORCID-Profile: Ayda Javanbakht, David Hanna, Grishma Amatya Jaspau, Ravi Sarode
Zitieren
APA
Javanbakht, A., Hanna, D., Jaspau, G. A., & Sarode, R. (2026). Implementation of soluble CD38 in blood crossmatching for patients on anti‐ CD38 therapy: A single‐center experience. Transfusion, 66(11), 2097-2100. https://doi.org/10.1111/trf.70389
Vancouver
Javanbakht A, Hanna D, Jaspau GA, Sarode R. Implementation of soluble CD38 in blood crossmatching for patients on anti‐ CD38 therapy: A single‐center experience. Transfusion. 2026;66(11):2097-2100. doi:10.1111/trf.70389
BibTeX
@article{Javanbakht2026,
author = {Javanbakht, Ayda and Hanna, David and Jaspau, Grishma Amatya and Sarode, Ravi},
title = {Implementation of soluble CD38 in blood crossmatching for patients on anti‐ CD38 therapy: A single‐center experience},
journal = {Transfusion},
year = {2026},
volume = {66},
number = {11},
pages = {2097--2100},
doi = {10.1111/trf.70389}
}
EUVIMED